Wedbush Estimates Biogen’s Q1 Earnings (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB) – Wedbush lowered their Q1 2025 EPS estimates for Biogen in a research note issued on Wednesday, April 16th. Wedbush analyst L. Chico now forecasts that the biotechnology company will post earnings per share of $3.51 for the quarter, down from their previous estimate of $3.82. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Wedbush also issued estimates for Biogen’s Q4 2026 earnings at $3.97 EPS, FY2026 earnings at $17.02 EPS and FY2027 earnings at $17.83 EPS.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, topping the consensus estimate of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%.

Several other analysts have also weighed in on BIIB. Wells Fargo & Company decreased their target price on shares of Biogen from $165.00 to $140.00 and set an “equal weight” rating on the stock in a research report on Thursday, February 13th. Canaccord Genuity Group decreased their price objective on Biogen from $298.00 to $265.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. The Goldman Sachs Group lowered their price objective on Biogen from $281.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Scotiabank cut their target price on Biogen from $244.00 to $224.00 and set a “sector outperform” rating for the company in a research report on Thursday, February 13th. Finally, Royal Bank of Canada lowered their price target on Biogen from $231.00 to $225.00 and set an “outperform” rating on the stock in a research report on Thursday, February 13th. Eighteen investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $213.15.

Biogen Stock Down 1.4 %

BIIB opened at $115.29 on Thursday. The company has a market capitalization of $16.88 billion, a P/E ratio of 10.30, a P/E/G ratio of 1.51 and a beta of 0.06. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.35 and a quick ratio of 0.90. The firm’s fifty day moving average price is $135.18 and its two-hundred day moving average price is $152.70. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $238.00.

Institutional Investors Weigh In On Biogen

Institutional investors have recently made changes to their positions in the stock. Larson Financial Group LLC boosted its holdings in Biogen by 640.9% during the fourth quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock worth $25,000 after buying an additional 141 shares during the last quarter. Lee Danner & Bass Inc. acquired a new stake in shares of Biogen in the 4th quarter valued at approximately $25,000. Opal Wealth Advisors LLC bought a new position in Biogen during the 1st quarter worth approximately $26,000. Colonial Trust Co SC grew its holdings in Biogen by 9,300.0% during the fourth quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 186 shares during the period. Finally, OFI Invest Asset Management acquired a new position in Biogen during the fourth quarter valued at approximately $32,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Biogen news, Director Stephen A. Sherwin sold 8,760 shares of the company’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the completion of the sale, the director now owns 11,318 shares in the company, valued at approximately $1,697,926.36. The trade was a 43.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.